Cargando…

Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs

It is impossible to conduct head-to-head trials of all the therapies to determine optimal treatment in the rapidly advancing era of therapies for metastatic renal cell carcinoma (mRCC). In this network meta-analysis,we aimed to compare efficacy and safety of first-line treatments for mRCC. We search...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Xiaofeng, Zhang, Fan, Liu, Tieshi, Yang, Rong, Ji, Changwei, Zhao, Xiaozhi, Xu, Linfeng, Liu, Guangxiang, Guo, Hongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941278/ https://www.ncbi.nlm.nih.gov/pubmed/26908455 http://dx.doi.org/10.18632/oncotarget.7511

Ejemplares similares

Trifecta outcomes of modified robot-assisted simple enucleation and standard robot-assisted partial nephrectomy for treating clinical T1b renal cell carcinoma
por: Zhao, Xiaozhi, et al.
Publicado: (2021)

Effect of extensive artery isolation during robotic-assisted partial nephrectomy on blood pressure of patients with poorly controlled hypertension: a preliminary study
por: Wang, Xin, et al.
Publicado: (2022)

Functional and oncologic outcomes of robot-assisted simple enucleation with and without renal arterial cold perfusion in complex renal tumors: a propensity score-matched analysis
por: Lu, Qun, et al.
Publicado: (2021)

Perioperative outcomes of zero ischemia radiofrequency ablation-assisted tumor enucleation for renal cell carcinoma: results of 182 patients
por: Zhang, Chengwei, et al.
Publicado: (2018)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
por: Qin, Suyang, et al.
Publicado: (2023)

The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways
por: Yang, Yang, et al.
Publicado: (2017)

Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs
por: Wang, Jianbao, et al.
Publicado: (2022)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
por: Lambrechts, Diether, et al.
Publicado: (2015)

Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs
por: Wang, J.-F., et al.
Publicado: (2014)

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs
por: Zhou, Yu, et al.
Publicado: (2020)

Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs
por: Pati, Ilaria, et al.
Publicado: (2022)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
por: Kadono, Yoshifumi, et al.
Publicado: (2023)

Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis
por: Zhu, Yiqi, et al.
Publicado: (2021)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
por: Manz, Kirsi M., et al.
Publicado: (2019)

Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma
por: Dupuis, Hugo Georges Arthur, et al.
Publicado: (2021)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs
por: Sun, Xifeng, et al.
Publicado: (2018)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
por: Kadono, Yoshifumi, et al.
Publicado: (2019)

Safety and efficacy of underwater versus conventional endoscopic mucosal resection for colorectal polyps: Systematic review and meta-analysis of RCTs
por: Chandan, Saurabh, et al.
Publicado: (2023)

Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
por: Bi, Pingping, et al.
Publicado: (2023)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

The Shiny Balancer - software and imbalance criteria for optimally balanced treatment allocation in small RCTs and cRCTs
por: Grischott, Thomas
Publicado: (2018)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
por: Hardy-Bessard, Anne-Claire, et al.
Publicado: (2020)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Inclusion and Analysis of Older Adults in RCTs
por: Van de Water, W., et al.
Publicado: (2011)

Drivers and barriers to patient participation in RCTs
por: Jenkins, V, et al.
Publicado: (2013)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
por: Badran, Ahmed, et al.
Publicado: (2020)

Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
por: Obinata, Daisuke, et al.
Publicado: (2022)

Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?
por: Ma, Wenliang, et al.
Publicado: (2020)

Meta-Analysis Based on Clinical RCTs: The Effect of Molecular Epimerism on the Safety of Glycyrrhizic Acid
por: Chen, Hongdou, et al.
Publicado: (2020)

Compare the efficacy of acupuncture with drugs in the treatment of Bell's palsy: A systematic review and meta-analysis of RCTs
por: Zhang, Rongchao, et al.
Publicado: (2019)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ep8govucvqt5g8h5k9mpjdnpg4